LpMab-19 Recognizes Sialylated O-Glycan on Thr76 of Human Podoplanin

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 35, Issue 5, 2016, Pages 245-253

  Ogasawara, Satoshi ^a   Kaneko, Mika K ^a   Kato, Yukinari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CasMab; glycopeptides; monoclonal antibody; PDPN; podoplanin

Indexed keywords

ARGININE; GLYCAN; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LPMAB 19; PODOPLANIN; SIALIC ACID; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MOUSE; NONHUMAN; ORAL CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; SIALYLATION;

EID: 84994044813     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2016.0031     Document Type: Article

References (54)

1. Tsuruo T, Kawabata H, Iida H, and Yamori T: Tumorinduced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. Clin Exp Metastasis 1986;4:25-33.
2. Sugimoto Y, Oh-hara T, Watanabe M, Saito H, Yamori T, and Tsuruo T: Acquisition of metastatic ability in hybridomas between two low metastatic clones of murine colon adenocarcinoma 26 defective in either platelet-aggregating activity or in vivo growth potential. Cancer Res 1987;47: 4396-4401.
3. Watanabe M, Okochi E, Sugimoto Y, and Tsuruo T: Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 1988;48:6411-6416.
4. Watanabe M, Sugimoto Y, and Tsuruo T: Expression of a Mr 41,000 glycoprotein associated with thrombinindependent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Res 1990;50:6657-6662.
5. Sugimoto Y, Watanabe M, Oh-hara T, Sato S, Isoe T, and Tsuruo T: Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res 1991;51:921-925.
6. Toyoshima M, Nakajima M, Yamori T, and Tsuruo T: Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. Cancer Res 1995;55:767-773.
7. Kato Y, Fujita N, Yano H, and Tsuruo T: Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule. Cancer Res 1997;57: 3040-3045.
8. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, et al.: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003;278:51599-51605.
9. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, et al.: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007;170:1337-1347.
10. Kaneko MK, Kato Y, Kitano T, and Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006;378: 52-57.
11. Kato Y, and Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014;4:5924.
12. KanekoMK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, et al.: Monoclonal antibody LpMab-9 recognizes Oglycosylated N-terminus of human podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34:310-317.
13. Kaneko MK, Oki H, Ogasawara S, Takagi M, and Kato Y: Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic legions of osteosarcoma. Monoclon Antib Immunodiagn Immunother 2015;34:154-161.
14. Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, et al.: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 2015;6:36003-36018.
15. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, et al.: Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34:318-326.
16. Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, et al.: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother 2015; 34:174-180.
17. Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi M, and Kato Y: Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother 2015;34: 44-50.
18. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, et al.: LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin. PLoS One 2016;11:e0152912.
19. Kato Y, Ogasawara S, Oki H, Honma R, Takagi M, Fujii Y, et al.: Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. Monoclon Antib Immunodiagn Immunother 2016;35:109-116.
20. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, et al.: Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin. Monoclon Antib Immunodiagn Immunother 2016;35:155-162.
21. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, et al.: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006;349:1301-1307.
22. Ogasawara S, Kaneko MK, Price JE, and Kato Y: Characterization of anti-podoplanin monoclonal antibodies: Critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008;27:259-267.
23. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, et al.: Evaluation of antipodoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010;37:785-794.
24. Fujii Y, KanekoM, NeyazakiM, Nogi T, Kato Y, and Takagi J:PAtag:Aversatile protein tagging systemusing a super high affinity antibody against a dodecapeptide derived fromhuman podoplanin. Protein Expr Purif 2014;95:240-247.
25. Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, et al.: Tailored placement of a turnforming PA tag into the structured domain of a protein to probe its conformational state. J Cell Sci 2016;129:1512-1522.
26. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, et al.: Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2013;132:2339-2348.
27. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, et al.: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibodydependent cellular cytotoxicity. Cancer Sci 2012;103:1913-1919.
28. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, et al.: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008;99:54-61.
29. Abdelmoula M, Spertini F, Shibata T, Gyotoku Y, Luzuy S, Lambert PH, et al.: IgG3 is the major source of cryoglobulins in mice. J Immunol 1989;143:526-532.
30. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, et al.: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013;8:e73609.
31. Nakazawa Y, Takagi S, Sato S, Oh-hara T, Koike S, Takami M, et al.: Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci 2011;102:2051-2057.
32. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, et al.: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
33. Kono T, Shimoda M, Takahashi M, Matsumoto K, Yoshimoto T, Mizutani M, et al.: Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int J Oncol 2007;31:501-508.
34. Sekiguchi T, Takemoto A, Takagi S, Takatori K, Sato S, Takami M, et al.: Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget 2016;7:3934-3946.
35. Hayatsu N, Ogasawara S, Kaneko MK, Kato Y, and Narimatsu H: Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells. Biochem Biophys Res Commun 2008;368:217-222.
36. Kaji C, Tsujimoto Y, Kato Kaneko M, Kato Y, and Sawa Y: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem 2012;45:227-237.
37. Honma R, Ogasawara S, Kaneko M, Fujii Y, Oki H, Nakamura T, et al.: PMab-44 detects bovine podoplanin in immunohistochemistry. Monoclon Antib Immunodiagn Immunother 2016. DOI:10.1089/mab.2016.0016.
38. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, et al.: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899-910.
39. Yuan P, Temam S, El-Naggar A, Zhou X, Liu D, Lee J, et al.: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107: 563-569.
40. Takagi S, Oh-Hara T, Sato S, Gong B, Takami M, and Fujita N: Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int J Cancer 2014;134:2605-2614.
41. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, and Fukayama M: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011;179:1041-1049.
42. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, et al.: Podoplanin expression in primary central nervous system germ cell tumors: A useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl) 2006;111:563-568.
43. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl) 2006;111: 483-488.
44. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, et al.: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 2013;190:6239-6249.
45. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, and Tsuruo T: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004;23:8552-8556.
46. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005;26:195-200.
47. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, et al.: Podoplanin expression by cancerassociated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011;59:1249-1260.
48. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, et al.: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008;123:1053-1059.
49. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, et al.: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res 2011;71: 4769-4779.
50. Schoppmann SF, JeschB,RieglerMF,Maroske F,Schwameis K, Jomrich G, et al.: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus.Clin ExpMetastasis 2013;30: 441-446.
51. Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, et al.: Podoplanin expression in cancerassociated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer 2013; 12:168.
52. Inoue H, Tsuchiya H, Miyazaki Y, Kikuchi K, Ide F, Sakashita H, et al.: Podoplanin expressing cancer-associated fibroblasts in oral cancer. Tumour Biol 2014;35:11345-11352.
53. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al.: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007;282:25993-26001.
54. Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, and Yamaguchi Y: A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014;22:1711-1721.